SSY Group Past Earnings Performance
Past criteria checks 5/6
SSY Group has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 11.6% per year. SSY Group's return on equity is 18.2%, and it has net margins of 17.5%.
Key information
2.5%
Earnings growth rate
1.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 11.6% |
| Return on equity | 18.2% |
| Net Margin | 17.5% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How SSY Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 6,434 | 1,123 | 1,950 | 259 |
| 30 Sep 22 | 6,376 | 1,101 | 2,020 | 267 |
| 30 Jun 22 | 6,318 | 1,080 | 2,090 | 237 |
| 31 Mar 22 | 5,838 | 933 | 2,040 | 224 |
| 31 Dec 21 | 5,357 | 786 | 1,990 | 248 |
| 30 Sep 21 | 5,139 | 713 | 2,025 | 212 |
| 30 Jun 21 | 4,921 | 641 | 2,060 | 175 |
| 31 Mar 21 | 4,591 | 626 | 1,977 | 151 |
| 31 Dec 20 | 4,261 | 612 | 1,894 | 127 |
| 30 Sep 20 | 4,177 | 723 | 1,766 | 88 |
| 30 Jun 20 | 4,093 | 835 | 1,638 | 50 |
| 31 Mar 20 | 4,364 | 985 | 1,641 | 25 |
| 31 Dec 19 | 4,636 | 1,136 | 1,643 | 0 |
| 30 Sep 19 | 4,525 | 1,075 | 1,628 | 0 |
| 30 Jun 19 | 4,414 | 1,014 | 1,613 | 0 |
| 31 Mar 19 | 4,297 | 963 | 1,590 | 0 |
| 31 Dec 18 | 4,181 | 912 | 1,566 | 0 |
| 30 Sep 18 | 4,012 | 867 | 1,477 | 0 |
| 30 Jun 18 | 3,844 | 822 | 1,387 | 0 |
| 31 Mar 18 | 3,460 | 743 | 1,175 | 0 |
| 31 Dec 17 | 3,076 | 665 | 962 | 0 |
| 30 Sep 17 | 2,827 | 616 | 826 | 0 |
| 30 Jun 17 | 2,577 | 567 | 689 | 0 |
| 31 Mar 17 | 2,469 | 528 | 652 | 0 |
| 31 Dec 16 | 2,361 | 490 | 615 | 0 |
| 30 Sep 16 | 2,315 | 426 | 620 | 0 |
| 30 Jun 16 | 2,270 | 363 | 624 | 0 |
| 31 Mar 16 | 2,246 | 383 | 591 | 0 |
| 31 Dec 15 | 2,222 | 403 | 559 | 0 |
| 30 Sep 15 | 2,189 | 443 | 533 | 0 |
| 30 Jun 15 | 2,156 | 482 | 507 | 0 |
| 31 Mar 15 | 2,124 | 487 | 496 | 0 |
| 31 Dec 14 | 2,091 | 492 | 484 | 0 |
| 30 Jun 14 | 1,309 | 402 | 233 | 0 |
| 31 Mar 14 | 1,516 | 386 | 330 | 0 |
| 31 Dec 13 | 1,723 | 369 | 427 | 0 |
| 30 Sep 13 | 2,681 | 386 | 766 | 0 |
| 30 Jun 13 | 2,618 | 359 | 743 | 0 |
| 31 Mar 13 | 2,524 | 320 | 722 | 0 |
| 31 Dec 12 | 2,431 | 281 | 701 | 0 |
| 30 Sep 12 | 2,360 | 127 | 708 | 0 |
Quality Earnings: LJUI.F has high quality earnings.
Growing Profit Margin: LJUI.F's current net profit margins (17.5%) are higher than last year (14.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LJUI.F's earnings have grown by 2.5% per year over the past 5 years.
Accelerating Growth: LJUI.F's earnings growth over the past year (42.9%) exceeds its 5-year average (2.5% per year).
Earnings vs Industry: LJUI.F earnings growth over the past year (42.9%) exceeded the Pharmaceuticals industry -17.3%.
Return on Equity
High ROE: LJUI.F's Return on Equity (18.2%) is considered low.